Browse

Prognostic factors in FIGO stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study

Cited 80 time in Web of Science Cited 94 time in Scopus
Authors
Lee, J-M; Lee, K-B; Nam, J-H; Ryu, S-Y; Bae, D-S; Park, J-T; Kim, S-C; Cha, S-D; Kim, K-R; Song, S-Y; Kang, S-B
Issue Date
2007-10-27
Publisher
Oxford University Press
Citation
Ann Oncol. 2008; 19(2): 321-326
Keywords
AdultAge FactorsAgedAged, 80 and overAnalysis of VarianceBiopsy, NeedleCarcinoma, Neuroendocrine/*mortality/pathology/*surgeryCarcinoma, Small Cell/*mortality/pathology/*surgeryChemotherapy, AdjuvantDisease-Free SurvivalFemaleHumansHysterectomy/methodsImmunohistochemistryKoreaMiddle AgedMulticenter Studies as TopicMultivariate AnalysisNeoplasm StagingProbabilityPrognosisProportional Hazards ModelsRadiotherapy, AdjuvantRegistriesRetrospective StudiesRisk AssessmentSurvival AnalysisTreatment OutcomeUterine Cervical Neoplasms/*mortality/pathology/*surgery
Abstract
BACKGROUND: To determine the clinical and pathologic prognostic factors in surgically treated patients with International Federation of Gynecology and Obstetrics (FIGO) stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix (SCNEC). PATIENTS AND METHODS: We retrospectively reviewed a total of 68 patients with FIGO stage IB-IIA SCNEC surgically treated from January 1997 to December 2003 in Korea. RESULTS: Of the 68 patients, 43 had FIGO stage IB1 SCNEC, 15 had stage IB2, and 10 had stage IIA. Seven were treated with radical surgery alone; 11 with neoadjuvant chemotherapy (NACT) followed by radical surgery; 24 with radical surgery followed by adjuvant chemotherapy; and 26 with radical surgery followed by adjuvant radiation or chemoradiation. After a median follow-up of 44 months (range, 6-113 months), the 2-year and 5-year survival rates for all patients were 64.6% and 46.6%, respectively. Univariate and multivariate analysis showed that FIGO stage was predictive of poor prognosis. Patients who received NACT showed poorer prognosis than those who did not receive NACT. Adjuvant chemoradiation did not improve survival compared with adjuvant chemotherapy alone. CONCLUSIONS: FIGO stage may act as a surrogate for factors prognostic of survival. Primary radical surgery followed by adjuvant chemotherapy is the preferred treatment modality for patients with early stage SCNEC.
ISSN
1569-8041 (Electronic)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17962205

http://annonc.oxfordjournals.org/cgi/reprint/19/2/321.pdf

http://hdl.handle.net/10371/68080
DOI
https://doi.org/10.1093/annonc/mdm465
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Obstetrics & Gynecology (산부인과전공)Journal Papers (저널논문_산부인과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse